China biotechnology: Morgan Stanley sees China biotech differentiation hinging on deeper clinical efficacy, safety, durability and therapeutic windows.

Overview

Morgan Stanley's Day 1 conference recap connects discussions with global healthcare companies to its China biotechnology coverage. The report argues that competitive differentiation will increasingly depend on clinically meaningful endpoints, long-term safety, durability and treatment practicality rather than headline response measures alone.

Core views

Morgan Stanley attended discussions with BNTX, MRK, AZN, MRNA, BIIB, Takeda, ALMS, JNJ, REGN and UTHR to frame competitive, regulatory and commercial implications for China biotech coverage. Its central conclusion is that clinical validation is becoming increasingly indication-specific, with differentiation determined by the endpoint that matters most in each disease rather than by broad class-level enthusiasm. In oral immunology, psoriasis competition is focused on depth of skin clearance, particularly PASI90/100, against TYK2 and approved oral IL-23 benchmarks. For atopic dermatitis, the report emphasizes chronic-safety profiles. In inflammatory bowel disease, the remission ceiling supports a role for combinations, while systemic lupus erythematosus development is more advanced around IFN/pDC, B-cell/BAFF, including telitacicept, and plasma-cell, including CM313, endotypes. For InnoCare, ICP-488's PASI90/100 depth data is the key comparison against an approved oral IL-23 benchmark, while ICP-332 requires chronic-safety follow-up. For Insilico, the IBD remission ceiling supports ISM5411's barrier-repair and immune-control rationale, while rentosertib may face UTHR's two-Phase-3 regulatory threshold. In oncology, personalised vaccines are gaining validation where tumour burden is low and checkpoint sensitivity is already established; upcoming renal-cell carcinoma and muscle-invasive bladder-cancer data will determine whether expansion into further indications is justified. Morgan Stanley views Everest's EVM16 Phase Ib investigator-initiated trial in post-resection, low-burden first-line NSCLC maintenance as consistent with this hypothesis, with pending data intended to guide expansion. For antibody-drug conjugates, the key debate is whether PD-(L)1/VEGF combinations can improve efficacy depth and durability without limiting dose exposure. Interest in next-generation IO-plus-ADC approaches is broadening, from BNTX's pumitamig combinations to MRK's MK-2010 exploration, but DualityBio's opportunity remains contingent on an adequate therapeutic window. In IgAN, competing pipelines may converge on proteinuria reduction, shifting differentiation to eGFR preservation and the duration of treatment-free time. Morgan Stanley therefore sees Keymed's CM313, RemeGen's telitacicept and Everest's Nefecon competing on preservation of kidney function and time off therapy rather than UPCR alone. In idiopathic pulmonary fibrosis, the report similarly argues that replication, additivity to background antifibrotics and durability of effect should shape adoption beyond headline FVC results. Morgan Stanley labels its Asia Pacific China healthcare industry view Attractive, indicating an expectation that the coverage universe will perform attractively versus the relevant broad-market benchmark over the next 12–18 months.

Analysis framework

The report uses conference discussions to compare disease-specific clinical benchmarks, regulatory requirements and commercial adoption criteria with the development cases of China biotech companies. It assesses differentiation through efficacy depth, safety, durability, functional endpoints, dosing feasibility and the therapeutic window of combination approaches.

Methodology notes

• Industry Analysis

  Disease-specific clinical benchmarking

  The report compares pipelines against the clinically relevant endpoint in each indication, such as PASI90/100 in psoriasis, remission in IBD, eGFR preservation in IgAN and FVC-related considerations in IPF, rather than relying on a single generic efficacy measure.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• InnoCare (9969.HK)

  Covered China biotech company with oral-immunology catalysts.

  Strengths

  ICP-488 can be assessed against the oral IL-23 benchmark through PASI90/100 depth data.

  Comparison

  Competes against TYK2 and approved oral IL-23 approaches in psoriasis.

  Risks

  ICP-332 awaits chronic-safety follow-up.

• Insilico (3696.HK)

  Covered China biotech company linked to IBD and fibrosis development discussions.

  Strengths

  The IBD remission ceiling supports ISM5411's barrier-repair plus immune-control rationale.

  Comparison

  Rentosertib may be judged against UTHR's two-Phase-3 regulatory requirement.

  Risks

  Potential regulatory hurdle for rentosertib.

• Everest (1952.HK)

  Covered China biotech company with oncology and IgAN-relevant programs.

  Strengths

  EVM16's trial design is consistent with the personalised-vaccine hypothesis in low-burden, checkpoint-sensitive disease.

  Weaknesses

  Expansion remains data-dependent.

  Comparison

  Nefecon may compete with CM313 and telitacicept on eGFR preservation and treatment-free duration.

  Risks

  Pending EVM16 data will determine the expansion path.

• DualityBio (9606.HK)

  Covered China biotech company exposed to next-generation IO-plus-ADC development.

  Strengths

  Growing interest in IO-plus-ADC combinations broadens the competitive context.

  Comparison

  The report cites BNTX pumitamig combinations and MRK's MK-2010 exploration as relevant activity.

  Risks

  The therapeutic window remains the key consideration.

Key data

• Industry viewAttractiveMorgan Stanley's view for its Asia Pacific China healthcare coverage universe.
• Industry-view horizon12–18 monthsAttractive denotes expected industry-universe performance versus the relevant broad-market benchmark over this period.
• EVM16 studyPhase Ib IITPost-resection, low-burden first-line NSCLC maintenance setting.
• Rentosertib regulatory benchmarkTwo Phase 3 trialsUTHR's stated regulatory bar referenced by the report.

Impact & implications

The report indicates that China biotech positioning will be shaped by evidence on clinically meaningful and durable outcomes. Companies may differentiate where their data demonstrate superior clearance depth, long-term safety, kidney-function preservation, durable time off therapy, combination feasibility or a sufficient therapeutic window.

Risks

• ICP-332 requires chronic-safety follow-up.
• Rentosertib may need to meet a two-Phase-3 regulatory bar.
• Whether PD-(L)1/VEGF combinations can improve ADC efficacy without impairing dose exposure remains unresolved.
• The therapeutic window remains critical for next-generation IO-plus-ADC approaches.
• EVM16 expansion depends on pending clinical data.

What to watch

• ICP-488 PASI90/100 depth data versus an approved oral IL-23 benchmark.
• Chronic-safety follow-up for ICP-332.
• Upcoming RCC and MIBC personalised-vaccine data.
• Pending EVM16 data in post-resection, low-burden first-line NSCLC maintenance.
• Evidence on eGFR preservation and durable treatment-free intervals in IgAN.